anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Because of high mortality associated with venous thrombosis (pulmonary embolism and deep venous thrombosis - DVT) the early recognition and therapeutics of its condition are crucial. Point of Care Ultrasound (POCUS) is a method with high sensibility to diagnose DVT and it is as accurate as Echo Doppler Ultrasound (EDUS), however the use of POCUS for diagnosis of DVT in the emergency care still presents resistance. This is a Clinical Trial on the use of POCUS for the diagnosis of DVT and its effect on length of hospital stay. 25 participants were randomized into two groups. The randomization was done through the random.org site in blocks of 4, a randomization list was with one researcher (blind) of the study. The experimental group was first submitted to POCUS in the Emergency Room, performed by a resident physician of Internal Medicine with training in POCUS, then after submitted to EDUS in the Radiology Service by a Radiologist. The control group was submitted only to EDUS in the Radiology Service. The 2-point compression technique was used, as described in previous studies, using the portable ultrasound device (M-turbo Sonosite) with a high frequency linear transducer (5-10 MHZ). The sites used in the evaluation were the popliteal site comprising the popliteal vein and trifurcation of the popliteal vein and the femoral point in which comprises the sapheno-femoral junction, the common femoral vein and the superficial femoral vein, all evaluated in the transverse plane. The result was considered positive for DVT when the vessel evaluated showed no compressibility and / or presented echogenic material in the lumen of the vein. After the randomization, the patients were followed for a period of 30 days, being evaluated in three moments: initial evaluation, at 7 and 30 days of the initial evaluation. Whenever possible, each evaluation was in person. In the initial evaluation, the participant's demographics, date and time of arrival at the Emergency Service, previous illnesses, Wells criteria score and reason for the initial care were collected. Participants randomized to the POCUS + EDUS group had recorded date and time of ultrasound at the bedside and, if there was confirmation of DVT, these data were collected by the resident physician, blinded for the Echo Doppler Ultrasound results. EDUS data, such as date and time of the examination request, date and time of the release of the exam report, confirmation of DVT, date and time of discharge were collected by another researcher, blinded to the participant's group and to the POCUS's results. After 7 and 30 days the outcomes were recorded: time for a first diagnostic information, time to therapeutic decision making / prescription, length of hospital stay, death, pulmonary thromboembolism, bleeding or other complication, re-hospitalization, evolution to DVT in cases that were initially negative.
The experimental group received 15 minutes of touch-observation and task-based mirror therapy program, followed by 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM \< 4.31), the mirror therapy program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
PURPOSE:To obtain a complex of mannan with a cancer cell differentiation inducer in which the effectiveness of the antitumor polysaccharide and that of the anticancer substance are enhanced and the side effects of the anticancer antibiotic are reduced by reacting activated mannan obtained by adding a cyanogen halide to an aqueous mannan solution with a spacer. CONSTITUTION:Mannan is dissolved in water, and a cyanogen halide is added to the solution to obtain activated mannan. The activated mannan is made to react with a spacer to obtain mannan into which the spacer is introduced. This mannan is made to react with a cancer cell differentiation inducer to obtain the title complex. An epsilon-amino-lower-alkanoic acid can be used as the above spacer, and usually a 4-8C epsilon-amino-n-alkanoic acid or the like is used. Cytosine arabinoside, azacytidine, cyclocytidine, mitomycin C, 5-fluorouracil or the like is used as the cancer cell differentiation inducer.
Enzyme activity is determined by various different mechanisms, including posttranslational modifications and allosteric regulation. Allosteric activators are often metabolites but other molecules serve similar functions. So far, examples of long non-coding RNAs (lncRNAs) acting as allosteric activators of enzyme activity are missing. Here, we describe the function of mitolnc in cardiomyocytes, a nuclear encoded long non-coding RNA, located in mitochondria and directly interacting with the branched-chain ketoacid dehydrogenase (BCKDH) complex to increase its activity. The BCKDH complex is critical for branched-chain amino acid catabolism (BCAAs). Inactivation of mitolnc in mice reduces BCKDH complex activity, resulting in accumulation of BCAAs in the heart and cardiac hypertrophy via enhanced mTOR signaling. We found that mitolnc allosterically activates the BCKDH complex, independent of phosphorylation. Mitolnc-mediated regulation of the BCKDH complex constitutes an important additional layer to regulate the BCKDH complex in a tissue-specific manner, evading direct coupling of BCAA metabolism to ACLY-dependent lipogenesis.
Colonization factors (CFs) are major virulence factors of enterotoxigenic Escherichia coli (ETEC). This pathogen is among the most common causes of bacterial diarrhea in children in low- and middle-income countries, travelers, and livestock. CFs are major candidate antigens in vaccines under development as preventive measures against ETEC infections in humans and livestock. Recent molecular studies have indicated that newly identified CFs on human ETEC are closely related to animal ETEC CFs. Increased knowledge of pathogenic mechanisms, immunogenicity, regulation, and expression of ETEC CFs, as well as the possible spread of animal ETEC to humans, may facilitate the future development of ETEC vaccines for humans and animals. Here, we present an updated review of CFs in ETEC.
Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m² are coated in ITENs and ITWS nets that will be installed to cover opened eaves and windows. This was manufactured by Moon Netting FZCO, United Arab Emirates.
The present invention relates to a health-care medicinal pillow, which belongs to a health-care medicinal pillow using Chinese herbal medicine as a pillow core and mainly treating rhinitis. The present invention is composed of a medicinal core and a breathable outer bag, and is characterized in that the medicinal core is composed of the following raw materials (by weight part): 1 to 8 parts of dahurian angelica root, 1 to 8 parts of red peony root, 1 to 8 parts of pogostemi herba, 1 to 8 parts of hemlock parsley, 1 to 12 parts of tooth soap, 0.2 to 8 parts of asarum, 1 to 12 parts of chrysanthemum, 1 to 12 parts of sweetgum fruit and 1 to 30 parts of peppermint. The present invention can treat rhinitis during the sleeping process by using the medicinal pillow for a long time, and the therapeutic efficacy is obvious. Through the verification of 290 rhinitis patients in clinic, generally speaking, obvious effect can be obtained after the health-care medicinal pillow is used for two weeks, and symptoms, such as snivel, headache, etc., can disappear basically. The symptoms of snivel and headache do not exist, and the healing rate can reach to 98%. The therapeutic cost is 1/10 of that of the traditional therapy, and the present invention mainly treats rhinitis.
After initial cleansing/debriding, patients in the improvised dressing group (2) will then have a thin layer zinc oxide paste applied to the dried periwound, carefully avoiding the open wound. A piece of a clean new plastic bag (food-grade World Star 1 mil LD bags, or the equivalent, purchased from the Papine Market across John Golding Road from the University of the West Indies), cut slightly larger than the ulcer will be gently conformed to the moist wound contours and sealed onto the zinc oxide paste. The bag will be fenestrated with a small slit using a number 11 scalpel or clean scissors prior to placing it on the ulcer in order to allow excess fluid to escape. The edges of the slit will be approximated. Clean gauze will be placed lightly over the slit to capture escaping fluid. One wrap of stretch gauze will hold the dressing in place. Patients will be instructed to change the dressings daily, irrigating with normal saline at each dressing change.
Objective: The aim of the study is to investigate the effects of exercises with flossband on balance, proprioception, and physical performance in the ankle.

Materials and Methods: Thirty-six football players were included in the study. As this was a serial group design the same football players were included in both the study group and the control group. There was a 72-hour break between the interventions for the study group and the control group. The study began with the study group. The study group received Flossband application while the control group received foam roller bandage application. The same exercises were conducted alongside both interventions. Measurements were taken before and after the interventions and exercises. Ankle dorsiflexion range of motion was evaluated using the weight-bearing lunge test, static balance using a smartphone application, dynamic balance using the Y-balance test, and proprioception using the joint position sense test. Additionally, the hop test was used to assess jumping performance.
FIELD: microbiological industry. SUBSTANCE: invention relates to production of probiotic for ruminant animals. Invention proposes the strain Lactobacillus acido-philus var. coccoideus M-86 VKPM B-4992. Strain is isolated from dominating gastroenteric tract microflora of healthy calf by method of accumulative culture in media MRS, Leonovitch, Perekopov at 28-30 C. Culture is isolated from monocolonies and identified by Bergey key. Strain shows technological effectiveness for production of probiotic under industrial conditions. EFFECT: strain indicated above, improved method of probiotic producing.
OBJECTIVE: This study aims to evaluate the endoprosthesis complications in patients undergoing TEVAR for blunt traumatic thoracic aortic injury, through long-term clinical and diagnostic follow-up.
METHODS: During the study interval (November 2000-October 2020), a total of 38 patients (63% male; average age 37.5 years) with thoracic aortic injury underwent thoracic endovascular aortic repair. Patients underwent routine follow-up with clinical examination and radiological evaluation (CT-angiography or MRI-angiography plus chest radiograph), scheduled at 1 month, at 6 months (only in the cases of thoracic aortic dissection), at 1 year after the procedure and every 1 year thereafter.
RESULTS: Technical success was achieved in 38 procedures (100%). The TEVAR-related mortality rate was 0%. No immediate major complications related to the endovascular procedure were observed. The median duration of diagnostic follow-up was 80 months. A total of four procedure-related complications (10.5%) were identified at the follow-up. Three (7.9%) distal infoldings and collapses of the thoracic endoprosthesis and one (2.6%) type Ia endoleak were observed. No thrombosis of the prosthesis, nor signs of aortic pseudocoarctation were identified. No further complications related to endograft (endoleaks, infections, rupture, partial or complete thrombosis) occurred. No changes in the native aorta, stenosis, or increases in the endograft's diameters were observed. A total of 20 patients (52.6%) underwent MRI-angiography examinations, while a total of 34 patients (89.5%) underwent chest radiographs at the follow-up. In all cases, CT-angiography examinations were performed at the follow-up.
CONCLUSIONS: Procedure-related complications were observed within one year of TEVAR, limiting concerns related to the durability of the prosthesis. No morphological changes in the aorta were observed despite long-term follow-up. The consequences of lifelong surveillance in terms of radiation exposure deserve special consideration, especially in younger patients treated for TAI.
All children receive routine antiemetic therapy before chemotherapy. Children in the experimental group will use the interactive mobile application (5inD) for seven days from the first day of chemotherapy. The games in this application will help distract their attention and manage their nausea and vomiting.
On the 0th and 1st postoperative days, patients in the intervention group will listen to white noise with a bluetooth headset for 30 minutes before going to sleep, and they will be kept under observation during this time.Patients in the control group will be monitored according to their routine clinical procedures. Since there are no procedures or interventions in clinical procedures, only patient monitoring will be performed. Patients in the control group will also be followed up at the same times and with the same forms.
Children aged between 6-16 years old will perform 5-10 minutes daily mindfulness and compassion training in school. The intervention will last for 10 weeks.
Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
Only parent caregivers of children with eczema will attend the six sessions. The content of the 2.5-hour parents group will be the same as the one in Arm 1 (Parent-child I-BMS intervention group), with an additional 0.5 hour of reflective discussion among group members. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
The present invention relates to novel pancreatic related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "pancreatic antigens", and the use of such pancreatic antigens for detecting disorders of the pancreas, particularly the presence of pancreatic cancer and pancreatic cancer metastases. More specifically, isolated pancreatic associated nucleic acid molecules are provided encoding novel pancreatic associated polypeptides. Novel pancreatic polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human pancreatic associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
During long-term administration, the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. The morning and evening doses do not have to be equal in size and the administration of the drug more frequently than twice daily is not necessary.

In patients who tolerate lower doses well, the dose may be increased to naproxen sodium 1650 mg/day for limited periods of up to 6 months when a higher level of anti-inflammatory/analgesic activity is required. When treating such patients with naproxen sodium 1650 mg/day, the physician should observe sufficient increased clinical benefits to offset the potential increased risk. The morning and evening doses do not have to be equal in size and administration of the drug more frequently than twice daily does not generally make a difference in response (see CLINICAL PHARMACOLOGY).
Dose expansion cohorts will be initiated to further confirm safety and optimal biologically active dose. Participants will receive ISB 2001 until disease progression, unacceptable toxicity occurs, any criterion for stopping the study treatment or participant withdrawal from the study.
Dosing: Patients should be advised to take WELCHOL Tablets with a meal and liquid. WELCHOL can be taken as 6 tablets once daily or 3 tablets twice daily. Patients should be advised to take WELCHOL for Oral Suspension as one 3.75 gram packet once daily or one 1.875 gram packet twice daily. To prepare, empty the entire contents of one packet into a glass or cup. Add ½ to 1 cup (4 to 8 ounces) of water, fruit juice, or diet soft drinks. Stir well and drink. WELCHOL for Oral Suspension should be taken with meals. To avoid esophageal distress, WELCHOL for Oral Suspension should not be taken in its dry form. Always mix WELCHOL for Oral Suspension with water, fruit juice, or diet soft drinks before ingesting [See Dosage and Administration(2)]

Drug interactions: Drugs with a known interaction with colesevelam (e.g., cyclosporine, glyburide, levothyroxine, oral contraceptives) should be administered at least 4 hours prior to WELCHOL. Drugs that have not been tested for interaction with colesevelam, especially those with a narrow therapeutic index (e.g., phenytoin), should also be administered at least 4 hours prior to WELCHOL. Alternatively the physician should monitor blood levels of the coadministered drug. [See Drug Interactions (7)]

Gastrointestinal: WELCHOL can cause constipation. WELCHOL is contraindicated in patients with a history of bowel obstruction. WELCHOL is not recommended in patients who may be at risk of bowel obstruction, including patients with gastroparesis, other gastrointestinal motility disorders, or a history of major gastrointestinal surgery. Patients should be instructed to consume a diet that promotes bowel regularity. Patients should be instructed to promptly discontinue WELCHOL and seek medical attention if severe abdominal pain or severe constipation occurs. Because of the tablet size, WELCHOL Tablets can cause dysphagia or esophageal obstruction and should be used with caution in patients with dysphagia or swallowing disorders. To avoid esophageal distress, WELCHOL for Oral Suspension should not be taken in its dry form. Always mix WELCHOL for Oral Suspension with water, fruit juice, or diet soft drinks before ingesting [See Warnings and Precautions (5.4)]

Hypertriglyceridemia and pancreatitis: Patients should be instructed to discontinue WELCHOL and seek prompt medical attention if the hallmark symptoms of acute pancreatitis occur (e.g., severe abdominal pain with or without nausea and vomiting). [See Warnings and Precautions (5.2)]
<P>PROBLEM TO BE SOLVED: To provide a pulpitis diagnostic system performing accurate and objective diagnosis of pulpitis.  <P>SOLUTION: The pulpitis diagnostic system 300 has an imaging fiber device 200 and a pulpitis diagnostic marker 100. The pulpitis diagnostic marker 100 contains an E-selectin antibody bonded to an outer surface of a liposome including indocyanine green. A silicon tube 420 is attached to a tip end of a fiber of the imaging fiber 210, and the silicon tube 420 is pressed against a side of a tooth affected with pulpitis. The pulpitis diagnostic marker 100 specifically bonds with the pulpitis inflammation site. Fluorescent light of indocyanine green is observed by a monitor 370 to perform accurate and objective diagnosis of pulpitis.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention discloses a traditional Chinese medicine and particularly relates to a traditional Chinese medicine for treating animal inner damage and a preparation method thereof. The medicine is prepared from the following raw material medicines in parts by weight: 30-50 parts of caulis spatholobi, 25-35 parts of pseudo-ginseng, 20-30 parts of bletilla, 15-25 parts of lysimachia christinae hance, 10-20 parts of flos carthami and 5 parts of liquorice. The medicine disclosed by the invention is simple in preparation method, novel in formula and low in cost, and has a safe, efficient and broad-spectrum medicine effect. The traditional Chinese medicine has the effects that no drug resistance is generated after medication and no recurrence exists after drug withdrawal. The traditional Chinese medicine simultaneously has the functions of promoting blood circulation and relaxing tendons, nourishing blood for regulating menstruation, stopping bleeding and dissipating stasis, eliminating swelling and promoting granulation, dispelling wind and reliving pains and diminishing inflammation and detoxifying. The traditional Chinese medicine is easy to getting of materials, convenient to use and free from any toxic and side effects.
Cleansing article comprises a fibre fleece whose fibres are bound together by a water insol. binder and have, homogeneously distributed in (part of) the fleece, a cosmetically acceptable, foam-forming cleaning agent adhered to the fibre material in dry condition. The fibre fleece is impregnated with an aq. prepn. of the cleaning agent and then dried. The aq. prepn. can be in the form of a soln., emulsion, coacervate or aq. gel. and may contain other additives, e.g. skin protecting agents, perfume, foram-reinforcing agents, preservatives and anti-oxidants. The cleansing article can be used for washing in the bath of under a shower. The article may be in the form of a rectangular pocket which can be used as a glove. The fleece can be made of natural or synthetic fibres, e.g. natural or regenerated cellulose, or synthetic polyamides, polyester, acrylonitrile or mixts. of such fibres. The binding agent holding the fibres may be a synthetic gum or resin, e.g. an acrylic acid ester resin.
Autophagy has been involved in protection of ischemia/reperfusion (I/R)-induced injury in many tissues including the brain. The upstream stimulatory factor 2 (Usf2) was proposed as a regulator in aging and degenerative brain diseases; however, the its role in autophagy during cerebral I/R injury remains unclear. Here, the middle cerebral artery occlusion (MCAO) operation was applied to establish an I/R mouse model. We showed that Usf2 was significantly upregulated in I/R-injured brain, accompanied by decreased levels of autophagy. Then, oxygen-glucose deprivation/recovery (OGD/R) treatment was used to establish a cellular I/R model in HT22 neurons, and lentiviral interference vector against Usf2 (LV-sh-Usf2) was used to infect the neurons. Our results showed that Usf2 was significantly upregulated in OGD/R-treated HT22 neurons that displayed an increased level in cell apoptosis and decreased levels in cell viability and autophagy, and interference of Usf2 largely rescued the effects of OGD/R on cell viability, apoptosis, and autophagy, suggesting an important role of Usf2 in neuron autophagy. In the mechanism exploration, we found that, as a transcription factor, Usf2 bound to the promoter of YTHDF1, a famous reader of N6-Methyladenosine (m6A), also induced by OGD/R, and promoted its transcription. Overexpression of YTHDF1 was able to reverse the improvement of Usf2 interference on viability and autophagy of HT22 neurons. Moreover, YTHDF1 suppressed autophagy to induce HT22 cell apoptosis through increasing m6A-mediated stability of Cdc25A, a newly identified autophagy inhibitor. Finally, we demonstrated that interference of Usf2 markedly improved autophagy and alleviated I/R-induced injury in MCAO mice.